Malignant News and Research

RSS
Nanoparticles packed with chemotherapy drug and coated with chitosan target cancer stem-like cells

Nanoparticles packed with chemotherapy drug and coated with chitosan target cancer stem-like cells

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Biontech, Siemens enter into strategic collaboration on manufacture of personalized cancer vaccines

Biontech, Siemens enter into strategic collaboration on manufacture of personalized cancer vaccines

Detroit-area patients contribute to national study that redefines diagnosis, treatment of glioma

Detroit-area patients contribute to national study that redefines diagnosis, treatment of glioma

Novogen’s chemotherapy drug Anisina proves as effective anti-cancer agent in animals

Novogen’s chemotherapy drug Anisina proves as effective anti-cancer agent in animals

Understanding of tumor biology opens new opportunities to conduct clinical trial for thoracic tumors

Understanding of tumor biology opens new opportunities to conduct clinical trial for thoracic tumors

Drugs used against impotence does not increase risk of malignant melanoma

Drugs used against impotence does not increase risk of malignant melanoma

New breath test could help diagnose oesophageal and gastric cancer in minutes

New breath test could help diagnose oesophageal and gastric cancer in minutes

Targeted molecular-imaging method could help identify early stages of prostate cancer

Targeted molecular-imaging method could help identify early stages of prostate cancer

PD linked to increased cancer risk in Asian population

PD linked to increased cancer risk in Asian population

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

ALK1 protein determines the extent of breast tumour's spread in the body

ALK1 protein determines the extent of breast tumour's spread in the body

Young thyroid cancer patients with lymph node involvement at increased risk of dying

Young thyroid cancer patients with lymph node involvement at increased risk of dying

Breakthrough discovery on element transformation could lead to new way for treating cancer with radiation

Breakthrough discovery on element transformation could lead to new way for treating cancer with radiation

Scientists identify two new key players involved in development of prostate cancer

Scientists identify two new key players involved in development of prostate cancer

MedUni Vienna uses new MR technique to classify adenomas

MedUni Vienna uses new MR technique to classify adenomas

Mesothelioma.us releases new case study that focuses on experimental treatments for mesothelioma

Mesothelioma.us releases new case study that focuses on experimental treatments for mesothelioma

Weill Cornell scientists reveal how XBP1 gene can trigger immune responses against ovarian tumors

Weill Cornell scientists reveal how XBP1 gene can trigger immune responses against ovarian tumors

Cell fusion triggers multiple genetic changes that convert normal cells to cancer cells

Cell fusion triggers multiple genetic changes that convert normal cells to cancer cells

Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.